UNASSIGNED: A prospective institutional database collected data of patients with LAPC treated with chemotherapy, mainly FOLFIRINOX, followed by SABR, which was delivered using magnetic resonance guided radiotherapy, 40 Gy in 5 fractions within two weeks. Primary endpoint was overall survival (OS). Cox regression analyses were performed to identify predictors for OS.
UNASSIGNED: Overall, 74 patients were included, median age 66 years, 45.9% had a KPS score of ≥90. Median OS was 19.6 months from diagnosis and 12.1 months from start of SABR. Local control was 90% at one year. Multivariable Cox regression analyses identified KPS ≥90, age <70, and absence of pain prior to SABR as independent favorable predictors for OS. The rate of grade ≥3 fatigue and late gastro-intestinal toxicity was 2.7%.
UNASSIGNED: SABR is a well-tolerated treatment in patients with unresectable LAPC following chemotherapy, with better outcomes when applied in patients with higher performance score, age <70 years and absence of pain. Future randomized trials will have to confirm these findings.
■前瞻性机构数据库收集了接受化疗的LAPC患者的数据,主要是FIRINOX,其次是SABR,使用磁共振引导放射治疗,40Gy在两周内的5个分数。主要终点是总生存期(OS)。进行Cox回归分析以确定OS的预测因子。
■总的来说,包括74例患者,中位年龄66岁,45.9%的KPS评分≥90分。中位OS为诊断后19.6个月,SABR开始后12.1个月。一年的本地控制率为90%。多变量Cox回归分析确定KPS≥90,年龄<70和SABR之前没有疼痛是OS的独立有利预测因子。≥3级疲劳和晚期胃肠道毒性的发生率为2.7%。
■SABR对化疗后不可切除的LAPC患者是一种耐受性良好的治疗方法。当应用于表现得分较高的患者时,结果会更好,年龄<70岁,没有疼痛。未来的随机试验将必须证实这些发现。